Establishment of the Ivermectin Research for Malaria Elimination Network: Updating the research agenda

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Chaccour, Carlos J ^a,b,c   Rabinovich, N Regina ^b,d   Slater, Hannah ^e   Canavati, Sara E ^f   Bousema, Teun ^g   Lacerda, Marcus ^h   Ter Kuile, Feiko ⁱ   Drakeley, Chris ^j   Bassat, Quique ^b,k   Foy, Brian D ^l   Kobylinski, Kevin ^m,n  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MAHIDOL UNIVERSITY   (Thailand)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h INSTITUTO LEÔNIDAS E MARIA DEANE   (Brazil)

ⁱ LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k Manhiça Health Research Center   (Mozambique)

^l Department of Environmental and Radiological Health Sciences   (United States)

^m ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

ⁿ Walter Reed Institute of Research   (United States)

more..

Author keywords

Endectocides; Ivermectin; Malaria elimination; Research agenda; Residual malaria transmission; Vector control

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; IVERMECTIN; PIPERAQUINE; INSECTICIDE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; EVIDENCE BASED MEDICINE; HUMAN; LOIASIS; MALARIA; MALARIA CONTROL; MATHEMATICAL MODEL; MEDICAL SOCIETY; MOSQUITO; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; UNITED STATES; ANIMAL; ANOPHELES; INSECT VECTOR; INSECTICIDE RESISTANCE; LOUISIANA; MOSQUITO CONTROL;

ANIMALS; ANOPHELES; INSECT VECTORS; INSECTICIDE RESISTANCE; INSECTICIDES; IVERMECTIN; MALARIA; MOSQUITO CONTROL; NEW ORLEANS;

EID: 84934981663     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0691-6     Document Type: Article

References (38)

1. WHO. World malaria report 2014. Geneva: World Health Organization; 2014.
2. Roberts L, Enserink M. Malaria. Did they really say... eradication? Science. 2007;318:1544-5.
3. Knox TB, Juma EO, Ochomo EO, Pates Jamet H, Ndungo L, Chege P, et al. An online tool for mapping insecticide resistance in major Anopheles vectors of human malaria parasites and review of resistance status for the Afrotropical region. Parasit Vectors. 2014;7:76.
4. WHO. Global plan for insecticide resistance management in malaria vectors (GPIRM). Geneva: World Health Organization; 2012.
5. Govella NJ, Ferguson H. Why use of interventions targeting outdoor biting mosquitoes will be necessary to achieve malaria elimination. Front Physiol. 2012;3:199.
6. Nyunt MH, Aye KM, Kyaw MP, Kyaw TT, Hlaing T, Oo K, et al. Challenges in universal coverage and utilization of insecticide-treated bed nets in migrant plantation workers in Myanmar. Malar J. 2014;13:211.
7. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010;362:896-905.
8. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med. 2010;362:717-25.
9. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010;202:113-6.
10. Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119-26.
11. Alout H, Krajacich BJ, Meyers JI, Grubaugh ND, Brackney DE, Kobylinski KC, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014;13:417.
12. Chaccour C, Irigoyen-Barrio A, Gil Royo AG, Martinez Urbistondo D, Slater H, Hammann F, et al. Screening for a slow-release formulation of ivermectin for malaria vector control. Malar J. 2015;14:102.
13. Kobylinski KC, Alout H, Foy BD, Clements A, Adisakwattana P, Swierczewski BE, et al. Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control. Am J Trop Med Hyg. 2014;91:655-62.
14. Ouedraogo AL, Bastiaens GJ, Tiono AB, Guelbeogo WM, Kobylinski KC, Ouedraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015;60:357-65.
15. Panchal M, Rawat K, Kumar G, Kibria KM, Singh S, Kalamuddin M, et al. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis. 2014;5, e994.
16. Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210:1972-80.
17. Steketee RW, Ter Kuile FO. Ivermectin as a complementary strategy to kill mosquitoes and stop malaria transmission? Clin Infect Dis. 2014;60:366-8.
18. Malaria Eradication Scientific Aliance (MESA). MESA Track [ http://www.malariaeradication.org/mesa-track ] (accessed 4 april 2015)
19. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350:18-22.
20. The Mectizan Expert Committee and The Technical Consultative Committee. Recommendations for the treatment of Onchocerciasis with Mectizan in areas co-endemic for Onchocerciasis and Loiasis. Georgia, USA: (APOC) APfOC; 2004.
21. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.
22. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407-10.
23. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGready R, et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2010;66:705-12.
24. Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, et al. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother. 2014;58:2052-8.
25. Kobylinski KCP, Alongkot UR, Schuster A, McCardle W, Foy BD, Tarning J, et al. Assessing ivermectin susceptibility of Greater Mekong Subregion malaria vectors. Poster session Annual meeting of the American Society of Tropical Medicine and Hygiene; 2014 Nov 2-6; New Orleans.
26. Naz SM, Maqbool A, Ahmad M, Ahmad A, Zaman S. Efficacy of ivermectin for control of zoophilic malaria vectors in Pakistan. Pakistan J Zool. 2013;45:1585-91.
27. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85:3-5.
28. Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, et al. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9:365.
29. Kobylinski KC, Foy BD, Richardson JH. Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae. Malar J. 2012;11:381.
30. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.
31. Pacque M, Munoz B, Greene BM, Taylor HR. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment. J Infect Dis. 1991;163:381-5.
32. WHO. Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization; 2012.
33. Nunes JK, Woods C, Carter T, Raphael T, Morin MJ, Diallo D, et al. Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward. Vaccine. 2014;32:5531-9.
34. Okeibunor JC, Amuyunzu-Nyamongo M, Onyeneho NG, Tchounkeu YF, Manianga C, Kabali AT, et al. Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa. Trop Med Int Health. 2011;16:608-21.
35. The Ivermectin Research for Malaria Elimination Network [ http://www.ivermen.org ]. (accessed 19 may 2015).
36. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42:1122-33.
37. Lespine A, Menez C, Bourguinat C, Prichard RK. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2012;2:58-75.
38. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998;28:313-21.